Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen.

[1]  Ruth Etzioni,et al.  Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States. , 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[2]  John T. Wei,et al.  Use of the MyProstateScore (MPS) Test to Rule Out Clinically-Significant Cancer: Validation of a Straightforward Clinical Testing Approach. , 2020, Journal of Urology.

[3]  J. Brooks,et al.  17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  V. Laudone,et al.  Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. , 2019, European urology.

[5]  S. Serni,et al.  Adverse pathology after radical prostatectomy: the prognostic role of cumulative cancer length >6-mm threshold in prostate cancer–positive biopsies , 2019, Prostate International.

[6]  T. H. van der Kwast,et al.  A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. , 2019, European urology.

[7]  D. Lu,et al.  Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging. , 2019, European urology.

[8]  John T. Wei,et al.  Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. , 2019, European urology focus.

[9]  Predictors of adverse pathologic features after radical prostatectomy in low-risk prostate cancer , 2018, BMC Cancer.

[10]  H. Bang,et al.  Prostate-Specific Antigen–Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force , 2018, JAMA.

[11]  Jonathan I. Epstein,et al.  Longitudinal Assessment of Urinary PCA3 for Predicting Prostate Cancer Grade Reclassification in Favorable Risk Men during Active Surveillance , 2017, Prostate Cancer and Prostatic Diseases.

[12]  D. Sjoberg,et al.  The 4Kscore Predicts the Grade and Stage of Prostate Cancer in the Radical Prostatectomy Specimen: Results from a Multi-institutional Prospective Trial. , 2017, European urology focus.

[13]  John T. Wei,et al.  Association Between Combined TMPRSS2: ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer , 2017, JAMA oncology.

[14]  Geert Trooskens,et al.  Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. , 2016, European urology.

[15]  Javed Siddiqui,et al.  Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. , 2016, European urology.

[16]  H. Hricak,et al.  Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference , 2016, European Radiology.

[17]  John T. Wei,et al.  Assessment of long‐term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy , 2015, Cancer.

[18]  T. Tammela,et al.  Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening , 2015, Clinical Cancer Research.

[19]  David C. Miller,et al.  Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. , 2015, European urology.

[20]  Yair Lotan,et al.  Can urinary PCA3 supplement PSA in the early detection of prostate cancer? , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Lori J Sokoll,et al.  Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. , 2014, Urology.

[22]  Ruth Etzioni,et al.  Overdiagnosis and overtreatment of prostate cancer. , 2014, European urology.

[23]  T. D. de Reijke,et al.  Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. , 2014, European urology.

[24]  Yair Lotan,et al.  Systematic review of complications of prostate biopsy. , 2013, European urology.

[25]  T. H. van der Kwast,et al.  Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam. , 2013, European urology.

[26]  John T. Wei,et al.  Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study , 2013, Clinical Cancer Research.

[27]  G. Andriole,et al.  Risk-based prostate cancer screening. , 2012, European urology.

[28]  M. Gleave,et al.  Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence , 2011, BJU international.

[29]  L. Salomon,et al.  Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. , 2011, European urology.

[30]  A. Haese*,et al.  Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. , 2011, European urology.

[31]  Erik Holmberg,et al.  Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. , 2010, The Lancet. Oncology.

[32]  J. Witjes,et al.  Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results , 2008, The Prostate.

[33]  I. Tuerk,et al.  Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis. , 2008, European urology.

[34]  A. Zlotta,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Glea- son Grading of Prostatic Carcinoma , 2006 .

[35]  L. Kiemeney,et al.  DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. , 2002, Cancer research.